With the progress of society, many people’s living standards have improved, but due to work or family reasons they have ignored their own health problems, allowing some diseases to take advantage of it. Among them, colorectal cancer is a typical example. Colorectal cancer does not happen overnight. According to statistics, the time it takes a mutant cell to grow into a malignant tumor actually exceeds 30 years on average. And just inadvertently, a tiny lifestyle habit may be playing a role in carcinogenesis, and it is impossible to prevent it. In recent years, colorectal cancer has closely followed lung cancer and has become the second highest incidence cancer, which has to attract people’s attention.
Aniq davolash kolorektal saraton kasallariga yangi umid baxsh etadi
With the deepening of research on the efficacy of targeted therapy and genotyping, targeted drugs have become a new option for individualized treatment and comprehensive treatment of patients with colorectal cancer. First-line treatment. The emergence of targeted drugs has improved the treatment expectations of patients with colorectal cancer, and its combination with chemotherapy drugs has further extended the survival time of patients.
Commonly used targeted drugs for the treatment of colorectal cancer mainly include two types of drugs that target epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF), such as the former cetuximab and panib Monoclonal antibodies, the latter of which are ramucirumab, bevacizumab and regorafenib. Targeted drugs such as KRAS, BRAF, PIK3CA, MSI and PD-L1 have also entered clinical trials, and it is believed that more targeted drugs will be available in the near future to benefit patients with colorectal cancer.
Kolorektal saraton kasalligining individual farqlariga duch keling. Genlarni sinash juda zarur
Regarding the treatment of colorectal cancer, people are more concerned about what treatment methods are currently used? The treatment of colorectal cancer is related to the tumor stage, and the treatment should follow the principle of individualized treatment. How to achieve individualized treatment? The answer is, of course, genetic testing. Only through genetic testing to understand the molecular characteristics of cancer cells can we cure the disease. As mentioned earlier, there are several targeted drugs already available, but is it enough to only detect the corresponding target of the drug? of course not.
Masalan, kolorektal saraton kasalligida RAS mutatsiyasiga qaratilgan dori mavjud emasligiga qaramay, kolorektal saraton kasalligida RAS genlarini aniqlash ham muhimdir. 2008 yildagi bir tadqiqot shuni ko'rsatdiki, KRAS yovvoyi tipidagi bemorlar uchun ketuximab monoterapiyasi eng yaxshi qo'llab-quvvatlovchi davolanish bilan taqqoslaganda (9.5 oy va 4.8 oy) bemorlarning operatsion tizimini sezilarli darajada uzaytirishi mumkin, ammo KRAS mutant bemorlari Ammo bundan foyda ko'rmadilar. Bu shuni ko'rsatadiki, EGFR bilan ketuximabdan foydalanish maqsad sifatida bemorlarda KRAS mutatsiyasini aniqlash kerak va genetik tekshiruv almashtirib bo'lmaydigan rol o'ynagan.
Ikkinchi avlod ketma-ketligiga asoslangan genetik tekshiruv endi bemorlarning ehtiyojlarini qondira olmaydi
Genetika tekshiruvi haqida gap ketganda, hamma birinchi navbatda DNK mutatsiyasini aniqlash uchun ikkinchi avlod ketma-ketligini o'ylaydi. Genetik tahlil orqali bemorlarni davolashga yo'naltirilgan mutatsion maqsadlari uchun simptomatik maqsadli dorilarni toping. Ammo saraton kasalligi bilan kasallangan bemorlar ikkinchi avlod sekvensiyasidan haqiqatan ham foyda ko'rishlari mumkinmi? Statistik ma'lumotlarga ko'ra, bemorlarning 10 foizdan kamrog'i mutatsiya maqsadlarini aniqlay oladi va hatto kamroq bemorlar maqsadli dori-darmonlardan foydalanishda davom etishlari va foyda olishlari mumkin. Ko'pgina bemorlar hali ham umrini uzaytirish uchun kimyoviy terapevtik dorilarni davolashga ishonadilar. Kimyoterapevtik dori tanlash uchun aniq tanlovlar mavjud. Ko'rsatmalarni ko'r-ko'rona nusxalash o'rniga, Qo'shma Shtatlar nafaqat maqsadli terapiyani boshqarishi, balki bemorlarni kimyoviy terapiyaga aniq yo'l-yo'riq ko'rsatishi mumkin bo'lgan texnologiyaga ega, aniq sinovlar orqali bemorlarning 95 foiziga davolanish bo'yicha ko'rsatmalar berilishi va undan foyda olishlari mumkin.
Caris ko'p platformali molekulyar tahlil bemorlar uchun birinchi tanlovdir
Maqsadli dori-darmonlarga rahbarlik qilishdan tashqari, u kimyoviy terapevtik preparatlarni tanlashga ham rahbarlik qilishi mumkin. Bu Amerika Qo'shma Shtatlari Kerisning ko'p platformali molekulyar profillash tahlilining eng katta xususiyati va shu bilan birga bemorlar ko'proq foyda ko'rishlari mumkin. Kerais ko'p platformali molekulyar tahlil, saraton kasallarining barcha turlari uchun, DNK, RNK va oqsil darajalaridan o'smalarning molekulyar biologik xususiyatlarini har tomonlama tahlil qiladi, FDA tomonidan tasdiqlangan 60 dan ortiq dori-darmonlarni tanlash imkoniyatini beradi va 127,000 mingta o'sma xaritasini tahlilini yakunlaydi. , Saraton kasalligining 95% klinik jihatdan foyda keltirishi mumkin.
Keruisi rasmiy ma'lumotlariga ko'ra, 1180 bemorni qamrab olgan katta qattiq o'sma tekshiruvi, Keruisi ko'p platformali molekulyar tahlilidan so'ng, bemorlarning 422 kunga uzoq umr ko'rishlari. Ko'rsatma bo'yicha bemorlar tomonidan qo'llaniladigan dori-darmonlarning o'rtacha soni 3.2 ni, yo'riqsiz bemorlar tomonidan qo'llaniladigan dori-darmonlarning soni 4.2 ni tashkil etdi. Ko'proq dori-darmonlar bemorlarga ko'proq nojo'ya ta'sirlarni va keraksiz iqtisodiy yo'qotishlarni keltirib chiqarishi kerakligini anglatardi. Bemorlarning tasavvurida bo'lmagan narsa, maqsadli dori-darmonlarni tanlashga rahbarlik qilishdan tashqari, Keruisi qaysi kimyoviy terapevtik preparatlar bemorlarga mos kelishini ham tahlil qilishi mumkin. Ko'pgina odamlar maqsadli terapiya maqsadli dori-darmonlarni tanlash uchun gen mutatsiyalariga asoslanganligini aniq bilishadi, ammo aslida kimyoviy terapiya bo'yicha dori-darmonlarni tanlashda ham ko'rsatmalarga ehtiyoj bor va ularni davolash ko'rsatmalariga muvofiq nusxa ko'chirish mumkin emas. Keris ko'p platformali molekulyar tahlillari bemorlarga eng to'g'ri va mos davolash usullarini taqdim etadigan bunday keng qamrovli tahlil texnologiyasidir.
Keruis molekulyar tahlilining eng foydali saratonlari o'pka saratoni, kolorektal saraton va ko'krak saratonidir. Bemorlar Keruis molekulyar tahlilidan quyidagi holatlarda, masalan, dori-darmonlarga chidamliligi bilan metastatik saratonni standart davolashda foydalanishlari mumkin: masalan, kolorektal saraton, o'pka saratoni, ko'krak saratoni va tuxumdon saratoni; kamdan-kam uchraydigan saraton turlari: sarkoma, glia stromal o'smalar, noma'lum asosiy fokusli metastatik karsinoma; malign o'smalar uchun deyarli hech qanday tanlash mezonlari: melanoma, oshqozon osti bezi saratoni kabi.
Kolorektal saraton kasalligi ushbu imkoniyatni qadrlashi kerak. Keruisning ko'p platformali molekulyar tahlili orqali ular saraton xaritasining xususiyatlarini har tomonlama olishlari mumkin. Mutatsiya maqsadi bo'lmasa ham, Keruisi qaysi dorilar klinik jihatdan foyda keltirishi va qaysi biri kimyoviy terapiyadan foydalana olmasligini ko'rsatishi mumkin. Bemorlarga keraksiz nojo'ya ta'sirlardan saqlanish uchun.
